Telegene efluvium post-COVID
DOI:
https://doi.org/10.33448/rsd-v11i8.30452Keywords:
Telogen effluvium; COVID-19; Loss of hair; Health teaching.Abstract
Introduction: Hair has a vast importance in appearance and self-esteem, telogen effluvium increases hair loss, from 100 to 400 hairs/day, and may be associated with COVID-19, because of medications, emotional stress and alteration of the hair cycle because of the SARS-CoV-2 virus. Objective: Literature review on the relationship of telogen effluvium post COVID-19. As well as associating the relationship of symptoms, it has the relationship with hair loss. Method: For the development of the following integrative review, the following databases were used: VHL, PubMed. The inclusion criteria were: articles with full text available for reading, published in English, Portuguese or Spanish. Result: The articles found had several opinions not finding the exact cause of which the virus induces hair loss, which may be related to the medication, emotional stress, symptoms of the disease itself such as high fever. Even the virus not distinguishing sex is more reported in women. Conclusion: Since the exact cause of telogen effluvium after COVID-19 is not known, there is no specific treatment for the cases and should follow the same guidelines already existing for telogen effluvium in dermatology.
References
Aksou, H. et al. (2021). COVID‐19 induced telogen effluvium. Dermatologic Therapy. 34, 15175.
Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A. Review of the Literature. Cureus 12(5):e8320.
Asghar, F. et al. (2020). Telogen effluvium: a review of the literature. Cureus, 12,5
Avé, M., & Igreja, A. C. (2013). Eflúvio telógeno.. Atlas de dermatologia:da semiologia ao diagnóstico, 104-104.
Bergfeld, W. (2019). Telogen efluvium. In: UpToDate, Hordinsky M, Ofori AO editors. Waltham (MA).
Brenner, F.A., & Bergfeld, W.F. (1999). Understanding Telogen Effluvium. Anais Brasileiros de Dermatologia.
Cline, A., Jacobs, A.K., Fonseca, M., Wu, J., Asrani, F., Safai, B., et al. Race, ethnicity, and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID-19 pandemic. J Am Acad Dermatol.
Fernandes, I.M. et al. (2021). Manifestações dermatológicas durante e após a COVID-19: uma revisão narrativa. Brazilian Journal of Health Review, 4, 5.
Gameros, P.C. & Cordeiro, S. L. (2018). El pelo: generalidades y enfermedades más comunes. Revista de la Facultad de Medicina de la Universidad Nacional Autonoma de México, 61, 48-56.
Ghebreyesus, T. (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19. World Health Organization, 11, 2020.
Gupta, A. et al. (2020). Extrapulmonary manifestations of COVID-19. Nature medicine, 26, 1017-1032.
Helmy, Y. et al. (2020). The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Journal of clinical medicine, 9, 1225.
Hunt, N., & McHale, S. (2005). The psychological impact of alopecia. BMJ (Clinical research ed.), 331(7522), 951–953.
Hussain, N. et al. (2021). A systematic review of acute telogen effluvium, a harrowing post‐COVID‐ 19 manifestation. Journal of medical virology.
Izumi, M.O. & Brandão. B.J.F. (2021). Tratamento do eflúvio telógeno pós-Covid 19. BWS Journal. 4, 1-8.
Mieczkowska, K., Deutsch, A., Borok, J., Guzman, A. K., Fruchter, R., Patel, P., & Halverstam, C. P. (2021). Telogen effluvium: a sequela of COVID‐19. International Journal of Dermatology.
Millett, G. A., Jones, A. T., Benkeser, D., Baral, S., Mercer, L., Beyrer, C. & Sullivan, P. S. (2020). Assessing differential impacts of COVID-19 on black communities. Annals of epidemiology,47, 37-44.
Nykolaichuk, K., Kuhta,О., & Senchuk, L. (2021). Pós-covid-19 telogen effluvium. Wha tis the razon? InterConf. 302-306.
Olds, H. et al. (2021). Telogen effluvium associated with COVID-19 infection. Dermatologic therapy, 34, 2.
Pereira, M. P. (2006). Eflúvio telógeno após dermatite de contato no couro cabeludo. Ana. Bra.Dermatol. 81(3).
Rivetti, N., & Barruscotti, S. (2020). Gestão do eflúvio telógeno durante a emergência COVID ‐ 19: implicações psicológicas. Terapia dermatológica.
Rizzetto, G. et al. (2021). Telogen effluvium related to post severe Sars‐Cov‐2 infection: clinical aspects and our management experience. Dermatologic therapy. 34, 14547.
Rossi, A. et al. (2021). Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disorders. 7, 377-381.
Ryder, M. L. (1965). Wool ®bre shedding and seasonal variation in wool growth. Proc R Soc Med 58: 806-8.
Starace, M. et al. (2021). Trichodynia and telogen effluvium in COVID-19 patients: Results of na international expert opinion suryey on diagnosis and management. JAAD international. 5, 11-18.
Stenn, K. S., Parimoo, S. & Prouty, S. (1998). Growth of the hair follicle: a cycling and regenerating biological system. In Molecular Basis of Epithelial Appendage Morphogenesis (Chuong C-M, ed.). RG Landes Company, Austin, TX. 1998:pp 111-30
Stenn, K. S. & Paus, R. (2001). Hair follicle growth controls. Physiol Rev. 81:449-94
Tammaro, A. et al. (2022). Hair and nail manifests of COVID-19. Journal of Cosmetic Dermatology, 1-8.
Turkmen, D. et al. (2020). Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire. Dermatologic Therapy, 33, 13923.
Watras, M. M., Patel, P.J., Arya, R. (2016). Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of Literature. Drugs - Real World Outcomes. 3, 1-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mayara Gabrielle Miranda Almeida ; Carla Beatriz Miranda Almeida; Tiberio Cesar Lima de Vasconcelos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
